» Articles » PMID: 23497035

Betaine Supplement Alleviates Hepatic Triglyceride Accumulation of Apolipoprotein E Deficient Mice Via Reducing Methylation of Peroxisomal Proliferator-activated Receptor Alpha Promoter

Overview
Publisher Biomed Central
Date 2013 Mar 19
PMID 23497035
Citations 38
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Betaine is a methyl donor and has been considered as a lipotropic effect substance. But its mechanism remains unclear. Hepatic steatosis is associated with abnormal expression of genes involved in hepatic lipid metabolism. DNA methylation contributes to the disregulation of gene expression. Here we hypothesized that betaine supplement and subsequent DNA methylation modifications alter the expression of genes that are involved in hepatic lipid metabolism and hence alleviate hepatic triglyceride accumulation.

Methods: Male wild-type (WT) C57BL/6 mice (n = 6) were fed with the AIN-93 G diet. ApoE-/- mice (n = 12), weight-matched with the WT mice, were divided into two groups (n = 6 per group), and fed with the AIN-93 G diet and AIN-93 G supplemented with 2% betaine/100 g diet. Seven weeks after the intervention, mice were sacrificed. Liver betaine, choline, homocysteine concentration were measured by HPLC. Liver oxidants activity and triglyceride level were assessed by ultraviolet spectrophotometry. Finally, hepatic PPAR alpha gene and its target genes expression levels and the methylation status of the PPAR alpha gene were determined.

Results: ApoE-/- mice had higher hepatic triglyceride and lower GSH-Px activity when compared with the WT mice. Betaine intervention reversed triglyceride deposit, enhanced SOD and GSH-Px activity in the liver. Interestingly, mice fed on betaine-supplemented diet showed a dramatic increase of hepatic choline concentration and a decrease of betaine and homocysteine concentration relative to the WT mice and the ApoE-/- mice absent with betaine intervention. Expression of PPAR alpha and CPT1 were decreased and expression of FAS was markedly increased in ApoE-/- mice. In parallel, PPAR alpha promoter methylation level were slightly increased in ApoE-/- mice though without significance. Betaine supplement upregulated expression of PPAR alpha and its target genes (CPT1, CYP2E1) and reversed hypermethylation of PPAR alpha promoter of ApoE-/- mice. Furthermore, PPAR alpha methylation was positively correlated with hepatic betaine concentration.

Conclusions: Our findings indicate that betaine supplement could alleviate hepatic triglyceride accumulation and improve antioxidant capacity by decreasing PPAR alpha promoter methylation and upregulating PPAR alpha and its target genes mRNA expression.

Citing Articles

Untargeted metabonomics and TLR4/ NF-κB signaling pathway analysis reveals potential mechanism of action of polysaccharide in nonalcoholic fatty liver disease.

Deng G, Zhao C, Cai X, Zhang X, Ma M, Lv J Front Pharmacol. 2024; 15:1374158.

PMID: 38887554 PMC: 11180771. DOI: 10.3389/fphar.2024.1374158.


Parental betaine supplementation promotes gosling growth with epigenetic modulation of IGF gene family in the liver.

Ma S, Wang Y, Chen L, Wang W, Zhuang X, Liu Y J Anim Sci. 2024; 102.

PMID: 38483185 PMC: 10980284. DOI: 10.1093/jas/skae065.


Maternal betaine supplementation ameliorates fatty liver disease in offspring mice by inhibiting hepatic NLRP3 inflammasome activation.

Li L, Sun L, Liang X, Ou Q, Tan X, Li F Nutr Res Pract. 2023; 17(6):1084-1098.

PMID: 38053832 PMC: 10694418. DOI: 10.4162/nrp.2023.17.6.1084.


Effects of low-energy diet supplemented with betaine on growth performance, nutrient digestibility, and serum metabolomic profiles in growing pigs.

Fu R, Liang C, Chen D, Tian G, Zheng P, He J J Anim Sci. 2023; 101.

PMID: 36930062 PMC: 10066726. DOI: 10.1093/jas/skad080.


Heat-Killed Inhibit FL83B Hepatic Lipid Accumulation and High Fat Diet-Induced Fatty Liver Damage in Rats by Activating Lipolysis through the Regulation the AMPK Signaling Pathway.

Lee J, Woo K, Hong J, Han K, Kim H, Kim T Int J Mol Sci. 2023; 24(5).

PMID: 36901915 PMC: 10002555. DOI: 10.3390/ijms24054486.


References
1.
Abdelmalek M, Sanderson S, Angulo P, Soldevila-Pico C, Liu C, Peter J . Betaine for nonalcoholic fatty liver disease: results of a randomized placebo-controlled trial. Hepatology. 2009; 50(6):1818-26. DOI: 10.1002/hep.23239. View

2.
Craig S . Betaine in human nutrition. Am J Clin Nutr. 2004; 80(3):539-49. DOI: 10.1093/ajcn/80.3.539. View

3.
Kohjima M, Enjoji M, Higuchi N, Kato M, Kotoh K, Yoshimoto T . Re-evaluation of fatty acid metabolism-related gene expression in nonalcoholic fatty liver disease. Int J Mol Med. 2007; 20(3):351-8. View

4.
Holm P, Ueland P, Kvalheim G, Lien E . Determination of choline, betaine, and dimethylglycine in plasma by a high-throughput method based on normal-phase chromatography-tandem mass spectrometry. Clin Chem. 2003; 49(2):286-94. DOI: 10.1373/49.2.286. View

5.
Folch J, Lees M, SLOANE STANLEY G . A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem. 1957; 226(1):497-509. View